Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.39 |
| ▸ | HTR3A | P46098 | 4/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22791289 | 0.91 | PTGDR2 (0.41) | PTGER4PTGDR2DRD4SIGMAR1TRPV1 | |
| SCHEMBL22791152 | 0.91 | PTGDR2 (0.41) | PTGER4PTGDR2DRD4SIGMAR1TRPV1 | |
| SCHEMBL22791290 | 0.91 | PTGDR2 (0.41) | PTGER4PTGDR2DRD4SIGMAR1TRPV1 | |
| SCHEMBL29614541 | 0.90 | PTGER4 (0.51) | PTGER4HTR3ABRD4PTGDR2DRD4 | |
| SCHEMBL22776476 | 0.90 | PTGER4 (0.51) | PTGER4HTR3ABRD4PTGDR2DRD4 | |
| SCHEMBL22777272 | 0.90 | PTGER4 (0.51) | PTGER4HTR3ABRD4PTGDR2DRD4 | |
| SCHEMBL22791249 | 0.89 | BRD4 (0.37) | PTGER4HTR3ABRD4PTGDR2DRD4 | |
| SCHEMBL22791199 | 0.89 | HTR4 (0.44) | BRD4DRD4 | |
| SCHEMBL29614436 | 0.86 | PTGER4 (0.38) | PTGER4HTR3ABRD4PTGDR2DRD4 | |
| SCHEMBL22791202 | 0.83 | ACSL1 (0.43) | PTGER4PTGDR2DRD4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020251957-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |